TOI vs AIOT

Analysts rate The Oncology Institute, Inc.

(TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, PowerFleet, Inc.

(AIOT) delivered a total return of -11. 5%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: AIOT returned -11. 5% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Oncology Institute, Inc.

(TOI) is the lower-risk stock at 1. 95β versus PowerFleet, Inc. 's 2. 71β — meaning AIOT is approximately 39% more volatile than TOI relative to the S&P 500.

On earnings-per-share growth, the picture is similar: PowerFleet, Inc.

grew EPS 60. 6% year-over-year, compared to 23. 9% for The Oncology Institute, Inc.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Oncology Institute, Inc.

(TOI) is the more profitable company, earning -12. 1% net margin versus -14. 1% for PowerFleet, Inc. — meaning it keeps -12. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AIOT leads at -7. 1% versus -7. 2% for TOI. At the gross margin level — before operating expenses — AIOT leads at 53. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AIOT (17.

8% yield) pays a dividend. TOI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, PowerFleet, Inc.

(AIOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (17. 8% yield). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIOT: -11. 5%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TOI (Healthcare) and AIOT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; AIOT is a small-cap income-oriented stock. AIOT pays a dividend while TOI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.